CLINICAL TRIALS PROFILE FOR ALIMTA
✉ Email this page to a colleague
All Clinical Trials for alimta
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00022646 ↗ | Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2001-08-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer. |
| NCT00022646 ↗ | Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Completed | Alliance for Clinical Trials in Oncology | Phase 2 | 2001-08-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer. |
| NCT00034463 ↗ | ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer | Completed | Eli Lilly and Company | Phase 1 | 1969-12-31 | This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer. |
| NCT00034502 ↗ | A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. | Completed | Eli Lilly and Company | Phase 1/Phase 2 | 1969-12-31 | This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with locally advanced or metastatic colorectal cancer. ALIMTA and irinotecan will be given every 21 days. |
| NCT00034593 ↗ | A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | Completed | Eli Lilly and Company | Phase 2 | 1969-12-31 | Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body. |
| NCT00034606 ↗ | Comparing 3 Schedules of Alimta Plus Gemzar | Completed | Eli Lilly and Company | Phase 2 | 1969-12-31 | The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for alimta
Condition Name
Clinical Trial Locations for alimta
Trials by Country
Clinical Trial Progress for alimta
Clinical Trial Phase
Clinical Trial Sponsors for alimta
Sponsor Name
